A Qualitative Systematic Review of the Evidence Base for Non-cross-resistance between Steroidal and Non-steroidal Aromatase Inhibitors in Metastatic Breast Cancer

Clinical Oncology

Volumn 23, Issue 3, 2011, Pages 209-215

  Beresford, M ^a   Tumur, I ^b   Chakrabarti, J ^b   Barden, J ^c   Rao, N ^c   Makris, A ^d  

^a BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c Decision Resources Group   (United Kingdom)

^d MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Aromatase inhibitor; Metastatic breast cancer; Systematic review

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; EXEMESTANE; FADROZOLE; FORMESTANE; FULVESTRANT; LETROZOLE; MEDROXYPROGESTERONE; MEGESTROL ACETATE; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; COCHRANE LIBRARY; CROSS RESISTANCE; CYTOLOGY; DIZZINESS; DRUG ERUPTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMBASE; EVIDENCE BASED PRACTICE; FATIGUE; HISTOLOGY; HOT FLUSH; HUMAN; MEDLINE; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL EDEMA; PRIORITY JOURNAL; QUALITATIVE RESEARCH; SIDE EFFECT; SURVIVAL TIME; SWEATING; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WEAKNESS;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; STEROIDS; TREATMENT OUTCOME;

EID: 79951950458     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2010.11.005     Document Type: Article

References (31)

1. Smith I.E., Dowsett M. Drug therapy: aromatase inhibitors in breast cancer. New Engl J Med 2003, 348:2431-2442.
2. Buzdar A.U., Powell K.C., Legha S.S., Blumenschein G.R. Treatment of advanced breast cancer with aminoglutethimide after therapy with tamoxifen. Cancer 1982, 50:1708-1712.
3. National Institute for Health and Clinical Excellence. Advanced breast cancer: diagnosis and treatment. NICE Clinical Guideline 81.
4. Lonning P.E. Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation?. Eur J Cancer 2009, 45:527-535.
5. Chia S., Gradishar W., Mauriac L., et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008, 26(10):1664-1670.
6. Bertelli G., Garrone O., Merlano M., et al. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. Oncology 2005, 69(6):471-477.
7. Carlini P., Michelotti A., Ferretti G., et al. Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients. Cancer Invest 2007, 25(2):102-105.
8. Lonning P.E., Bajetta E., Murray R., et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 2000, 18(11):2234-2244.
9. Chin Y.S., Beresford M.J., Ravichandran D., Makris A. Exemestane after non-steroidal aromatase inhibitors for post-menopausal women with advanced breast cancer. Breast 2007, 16(4):436-439.
10. Gennatas C., Michalaki V., Carvounis E., et al. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on letrozole or anastrozole. A phase II trial conducted by the Hellenic Group of Oncology (HELGO). Tumori 2006, 92(1):13-17.
11. Iaffaioli R.V., Formato R., Tortoriello A., et al. Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer. Br J Cancer 2005, 92(9):1621-1625.
12. Knoche A.J., Michaud L.B., Buzdar A.U. Efficacy of anastrozole in a consecutive series of advanced breast cancer patients treated with multiple prior chemotherapies and endocrine agents: M. D. Anderson Cancer Center experience. Breast 1999, 5(3):176-181.
13. Steele N., Zekri J., Coleman R., et al. Exemestane in metastatic breast cancer: effective therapy after third-generation non-steroidal aromatase inhibitor failure. Breast 2006, 15(3):430-436.
14. Thurlimann B., Paridaens R., Serin D., et al. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group. Eur J Cancer 1997, 33(11):1767-1773.
15. Coombes R.C., Kilburn L.S., Snowdon C.F., et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomized controlled trial. Lancet 2007, 369:559-570.
16. Coombes RC. Survival and safety post study treatment completion: an updated analysis of the Intergroup Exemestane Study (IES). Paper presented at: ECCO/ESMO2009.
17. Eastell R.A., Coleman R.E., Howell A., et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial. J Clin Oncol 2008, 26(7):1051-1057.
18. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. New Engl J Med 2009, 361(8):766-776. BIG 1-98 Collaborative Group.
19. Campos S.M., Guastalla J.P., Subar M., Abreu P., Winer E.P., Cameron D.A. A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. Clin Breast Cancer 2009, 9(1):39-44.
20. Johnston S.R.D. New strategies in estrogen receptor-positive breast cancer. Clin Cancer Res 2010, 16(7):1979-1987.
21. Ingle J.N., Suman V.J., Rowland K.M., et al. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy. J Clin Oncol 2006, 24:1052-1056.
22. Perey L., Paridaens R., Nole F., et al. Fulvestrant as hormonal treatment in postmenopausal patients with advanced breast cancer progressing after treatment with tamoxifen and aromatase inhibitors: update of a phase II SAK trial. Breast Cancer Res Treat 2004, 88:S236. for the Leuven University, Belgium, the Istituto Europeo di Oncologia, Milan, Italy and the Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland.
23. Steger G.G., Bartsch R., Wenzel C., et al. Fulvestrant in metastatic breast cancer. Breast Cancer Res Treat 2003, 82:S104.
24. Franco S., Perez A., Tan-chiu E., Frankel C., Vogel C.L. Response to fulvestrant in heavily pretreated postmenopausal women: a single center experience. Breast Cancer Treat Res 2004, 33:103-108.
25. Mello C.A.L., Chinen L.T.D., Da Silva S.C.S., et al. Prolonged to progression with fulvestrant for metastatic breast cancer. Med Oncol 2010, Epub ahead of print.
26. Dodwell D., Coombes G., Bliss J.M., et al. Combining fulvestrant (Faslodex TM) with continued oestrogen suppression in endocrine-sensitive advanced breast cancer: the SoFEA trial. Clin Oncol 2008, 20:321-324.
27. Bertelli G., Paridaens R. Optimal sequence of hormonotherapy in advanced breast cancer. Curr Opin Oncol 2006, 18(6):572-577.
28. Bonneterre J., Thürlimann B., Robertson J.F., et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000, 18(22):3748-3757.
29. Bonneterre J., Buzdar A., Nabholtz J.M., et al. Arimidex Writing Committee; Investigators Committee Members. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001, 92(9):2247-2258.
30. Thurlimann B., Robertson J.F.R., Nabholtz A., Buzdar A., Bonneterre J. Effect of tamoxifen following anastrozole compared with anastrozole following tamoxifen as first line treatment for advanced breast cancer in postmenopausal women. Eur J Cancer 2003, 39:2310. on behalf of the Arimidex Study Group.
31. Gibson L., Lawrence D., Dawson C., Bliss J. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database of Systematic Reviews 2009, 4. CD003370.